Combined Immunotherapy and Radiation Therapy for Non-Small Cell Lung Cancer

Inclusion Criteria

• Be 18 years of age or older
• Have confirmed diagnosis of Non-small cell lung cancer (NSCLC), Clinical Stage I/II lymph-node negative (T1 to T3N0M0)
• Be medically inoperable as determined by your physician or patient refusal of surgery
• Plan to receive stereotactic body radiation therapy (SBRT)

Exclusion Criteria

• Have active or prior autoimmune or inflammatory disorders
• Have history of another primary cancer
• Have history of organ transplantation
• Have active infection of Tuberculosis, Hepatitis B, Hepatitis C or HIV

Additional Info

• All patients will receive standard of care stereotactic body radiation therapy (SBRT), and will be randomly selected to receive either Durvalumab or placebo via intravenous (IV) infusion. Study treatment and physician visits will take place at Scripps Clinic Torrey Pines (Geisel Pavilion) and occur once monthly for up to two years.
• Search for NCT03833154 on www.clinicaltrials.gov for additional information.